A PHASE IV MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF SUNITINIB AS FIRST-LINE THERAPY IN CHINESE PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)

被引：0
|
作者：
Qin, S. [1 ]
Jin, J. [2 ]
Guo, J. [3 ]
Wang, J. [4 ,5 ]
Zhou, F. [6 ]
Huang, Y. [7 ]
Ren, X. [8 ]
Ye, D. [9 ]
Wang, Q. [10 ]
Pan, S. [11 ]
机构：
[1] Nanjing Bayi Hosp, Pla Canc Ctr, Nanjing, Peoples R China
[2] Peking Univ First Hosp, Beijing, Peoples R China
[3] Peking Univ Canc Hosp & Inst, Dept Renal Canc & Melanoma, Beijing, Peoples R China
[4] Peking Union Med Coll, Canc Hosp Inst, Beijing 100021, Peoples R China
[5] Chinese Acad Med Sci, Beijing 100730, Peoples R China
[6] Sun Yat Sen Univ, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China
[7] Shanghai Renji Hosp, Shanghai, Peoples R China
[8] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China
[9] Fudan Univ Shanghai Canc Ctr, Shanghai, Peoples R China
[10] Pfizer, Global Res & Dev, Shanghai, Peoples R China
[11] Pfizer, Clin Stat, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：282 / 282
页数：1
相关论文
共 50 条
  • [41] First-line everolimus followed by second-line sunitinib versus the opposite treatment sequence in patients with metastatic renal cell carcinoma (mRCC)
    Knox, J. J.
    Kay, A. C.
    Schiff, E.
    Hollaender, N.
    Rouyrre, N.
    Ravaud, A.
    Motzer, R. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [42] Comparative efficacy of sunitinib versus sorafenib as the first-line treatment for patients with metastatic renal cell carcinoma.
    Park, Seongjoon
    Lee, Jae-Lyun
    Park, Inkeun
    Park, Kwonoh
    Ahn, Yongchel
    Ahn, Jin-Hee
    Lee, Dae Ho
    Song, Cheryn
    Hong, Jun Hyuk
    Kim, Choung-Soo
    Ahn, Hanjong
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [43] CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure
    Masini, C.
    Vitale, M. G.
    Maruzzo, M.
    Procopio, G.
    De Giorgi, U.
    Buti, S.
    Rossetti, S.
    Iacovelli, R.
    Guida, A.
    Atzori, F.
    Mucciarini, C.
    Cosmai, L.
    Vignani, F.
    Prati, G.
    Scagliarini, S.
    Berselli, A.
    Pinto, C.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 : 17 - 17
  • [44] CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure
    Masini, C.
    Vitale, M. G.
    Maruzzo, M.
    Procopio, G.
    De Giorgi, U.
    Buti, S.
    Rossetti, S.
    Iacovelli, R.
    Guida, A.
    Atzori, F.
    Mucciarini, C.
    Scagliarini, S.
    Vignani, F.
    Prati, G.
    Cosmai, L.
    Berselli, A.
    Pinto, C.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [45] Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma
    Figlin, Robert A.
    Tannir, Nizar M.
    Uzzo, Robert G.
    Tykodi, Scott S.
    Chen, David Y. T.
    Master, Viraj
    Kapoor, Anil
    Vaena, Daniel
    Lowrance, William
    Bratslaysky, Gennady
    DeBenedette, Mark
    Gamble, Alicia
    Plachco, Ana
    Norris, Marcus S.
    Horvatinovich, Joe
    Tcherepanova, Irina Y.
    Nicolette, Charles A.
    Wood, Christopher G.
    [J]. CLINICAL CANCER RESEARCH, 2020, 26 (10) : 2327 - 2336
  • [46] A phase II study of the efficacy and safety of sunitinib in treatment-naive and pretreated Japanese patients (pts) with metastatic renal cell carcinoma (mRCC)
    Uemura, H.
    Shinohara, N.
    Naito, S.
    Akaza, H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [47] Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC)
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Negrier, S.
    Huang, X.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [48] OVERALL SURVIVAL WITH SUNITINIB VERSUS INTERFERON (IFN)-ALFA AS FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC)
    Negrier, S.
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Huang, X.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 190 - 190
  • [49] Impact of dose reduction on survival in patients starting sunitinib (SU) or pazopanib (PA) as first-line for metastatic renal cell carcinoma (mRCC).
    Iacovelli, Roberto
    Derosa, Lisa
    Massari, Francesco
    Verri, Elena
    Galli, Luca
    Ciccarese, Chiara
    Rocca, Maria Cossu
    Cianci, Claudia
    Bimbatti, Davide
    Aurilio, Gaetano
    Antonuzzo, Andrea
    Fantinel, Emanuela
    Cullura, Daniela
    Ricci, Sergio
    Modena, Alessandra
    Falcone, Alfredo
    Tortora, Giampaolo
    Nole, Franco
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [50] Characterizing prior nephrectomy patients with metastatic renal cell carcinoma (mRCC) treated with first-line sunitinib versus interferon-alfa
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bjarnason, G. A.
    Lin, X.
    Lowenthal, S. Pitman
    Korytowsky, B.
    Matczak, E.
    Oudard, S.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S644 - S645
12345